Covis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for COVIS, and what generic alternatives to COVIS drugs are available?
COVIS has sixteen approved drugs.
There are seventeen US patents protecting COVIS drugs.
There are one hundred and eighty-nine patent family members on COVIS drugs in forty-five countries and twenty-eight supplementary protection certificates in fourteen countries.
Drugs and US Patents for Covis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-005 | Jan 2, 2008 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
Covis | DUAKLIR PRESSAIR | aclidinium bromide; formoterol fumarate | POWDER, METERED;INHALATION | 210595-001 | Mar 29, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-004 | Jun 26, 2002 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Covis | TUDORZA PRESSAIR | aclidinium bromide | POWDER, METERED;INHALATION | 202450-001 | Jul 23, 2012 | RX | Yes | Yes | RE46417 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Covis | MAKENA | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 021945-001 | Feb 3, 2011 | AP1 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
Covis | BETAPACE AF | sotalol hydrochloride | TABLET;ORAL | 021151-002 | Feb 22, 2000 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-001 | Jun 26, 2002 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Covis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-006 | Jan 2, 2008 | 5,422,123 | See Plans and Pricing |
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-002 | Jan 10, 2008 | 5,695,743 | See Plans and Pricing |
Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-008 | Jan 2, 2008 | 5,422,123 | See Plans and Pricing |
Covis | ZETONNA | ciclesonide | AEROSOL, METERED;NASAL | 202129-001 | Jan 20, 2012 | 5,775,321 | See Plans and Pricing |
Covis | TUDORZA PRESSAIR | aclidinium bromide | POWDER, METERED;INHALATION | 202450-001 | Jul 23, 2012 | 6,071,498 | See Plans and Pricing |
Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-004 | Feb 2, 1995 | 4,703,038 | See Plans and Pricing |
Covis | ZETONNA | ciclesonide | AEROSOL, METERED;NASAL | 202129-001 | Jan 20, 2012 | 5,683,677 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for COVIS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 2 mg, 4 mg and 6 mg | ➤ Subscribe | 2007-08-10 |
➤ Subscribe | Nasal Spray | 250 mcg | ➤ Subscribe | 2012-02-13 |
➤ Subscribe | Extended-release Tablets | 25.5 mg and 34 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 8.5 mg and 17 mg | ➤ Subscribe | 2009-03-02 |
➤ Subscribe | Injection | 30 mg/mL, 17 mL single-use vials | ➤ Subscribe | 2015-12-04 |
➤ Subscribe | Extended-release Tablets | 20 mg and 30 mg | ➤ Subscribe | 2007-11-07 |
➤ Subscribe | Extended-release Tablets | 40 mg | ➤ Subscribe | 2007-06-11 |
International Patents for Covis Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 2265257 | See Plans and Pricing |
Denmark | 2953667 | See Plans and Pricing |
New Zealand | 585857 | See Plans and Pricing |
South Africa | 200200232 | See Plans and Pricing |
Denmark | 2954891 | See Plans and Pricing |
South Korea | 100854321 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2006079064 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Covis Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1169062 | 1290043-7 | Sweden | See Plans and Pricing | PRODUCT NAME: FERUMOXYTOL; REG. NO/DATE: EU/1/12/774/001 20120615 |
1411900 | SPC/GB11/015 | United Kingdom | See Plans and Pricing | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
1200431 | 2013C/001 | Belgium | See Plans and Pricing | PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT EN PARTICULIER LE BROMURE D'ACLIDINIUM; AUTHORISATION NUMBER AND DATE: EU/1/12/781/001 20120725 |
1411900 | 2011C/016 | Belgium | See Plans and Pricing | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
1200431 | C01200431/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: ACLIDINIUM; REGISTRATION NO/DATE: SWISSMEDIC 62590 25.04.2013 |
1200431 | 1390002-2 | Sweden | See Plans and Pricing | PRODUCT NAME: AKLIDINIUMSALT MED FARMACEUTISKT ACCEPTABEL ANJON AV EN- ELLER FLERVAERD SYRA, SPECIELLT AKLIDINIUMBROMID; REG. NO/DATE: EU/1/12/778/001 20120720 |
1169062 | 2012C/052 | Belgium | See Plans and Pricing | PRODUCT NAME: FERUMOXYTOL; AUTHORISATION NUMBER AND DATE: EU/1/12/774/001 20120620 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |